News

AstraZeneca (LSE:AZN) Anselamimab Shows Promise In AL Amyloidosis Despite Missing Main Endpoint
AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...
AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...
Yicai Global2d
Sino Biopharm to Buy Out LaNova for Up to USD951 Million, Heralding Potential M&A Wave
Sino Biopharm will buy the 95.1 percent of the Chinese developer of novel biologic drugs for cancer treatment that it does not already own, the Beijing-based company announced late on July 15. LaNova ...